OptimizeRx (OPRX) Liabilities and Shareholders Equity (2010 - 2026)

OptimizeRx has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $164.3 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 2.92% year-over-year to $164.3 million; the TTM figure through Jun 2026 stood at $678.8 million (up 0.8% YoY), while the FY2025 annual figure was $176.9 million, up 3.36% from the prior year.
• Liabilities and Shareholders Equity came in at $164.3 million for Q2 2026 at OptimizeRx, down from $167.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $183.4 million in Q4 2023 to a low of $121.3 million in Q2 2023.
• Average Liabilities and Shareholders Equity over 5 years is $156.5 million, with a median of $166.2 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity slipped 17.72% in 2023 and surged 42.49% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $134.7 million in 2022, then jumped by 36.18% to $183.4 million in 2023, then slipped by 6.66% to $171.2 million in 2024, then advanced by 3.36% to $176.9 million in 2025, then slipped by 7.12% to $164.3 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $164.3 million in Q2 2026, $167.3 million in Q1 2026, and $176.9 million in Q4 2025.